Klumair J, Pflanzer K
Rofo. 1977 Jan;126(1):66-9. doi: 10.1055/s-0029-1230535.
Sulphonyle ureas used in the oral treatment of diabetes occupy albumen-binding capacity. Hepatotropic contrast media therefore have difficulty with protein binding and renal excretion is increased. The proportion excreted through the kidneys has been determined in 50 diabetic patients on oral treatment. Demonstration of contrast in the urine was done radiologically, qualitative measurements by a subtraction method. As a control, the same group of patients were examined, having been taken off suphonyle ureas, as well as a group of 50 diabetic patients treated with insulin. While under medication, heteroptropic excretion rose on average to 55% and in some cases to 80%. This results in definite reduction of contrast filling of the biliary tree, occasionally to the extent of preventing a diagnosis. Displacement of sulphonyle urea by contrast was not observed.
用于糖尿病口服治疗的磺酰脲类药物占据蛋白结合能力。因此，亲肝性造影剂在蛋白结合方面存在困难，且肾排泄增加。已对50名接受口服治疗的糖尿病患者经肾排泄的比例进行了测定。通过放射学方法进行尿液造影显示，采用减法进行定性测量。作为对照，对同一组患者在停用磺酰脲类药物后进行了检查，以及对一组50名接受胰岛素治疗的糖尿病患者进行了检查。在用药期间，异向排泄平均上升至55%，在某些情况下升至80%。这导致胆管树造影剂充盈明显减少，偶尔会达到无法做出诊断的程度。未观察到造影剂对磺酰脲类药物的置换作用。
